Swiss National Bank
CERE

Swiss National Bank’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Swiss National Bank’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-143,200
Closed -$5.86M – 2501
2024
Q2 		$5.86M Hold
143,200
– – ﹤0.01% 1174
2024
Q1 		$6.05M Buy
143,200
+3,500
+3% +$147K ﹤0.01% 1174
2023
Q4 		$5.92M Buy
139,700
+1,800
+1% +$51.7K ﹤0.01% 1182
2023
Q3 		$3.01M Buy
137,900
+1,500
+1% +$37.5K ﹤0.01% 1587
2023
Q2 		$4.34M Buy
136,400
+1,400
+1% +$43K ﹤0.01% 1395
2023
Q1 		$3.29M Sell
135,000
-15,500
-10% -$455K ﹤0.01% 1530
2022
Q4 		$4.75M Buy
150,500
+9,800
+7% +$277K ﹤0.01% 1342
2022
Q3 		$3.98M Buy
140,700
+1,900
+1% +$56.6K ﹤0.01% 1413
2022
Q2 		$3.67M Buy
138,800
+34,400
+33% +$977K ﹤0.01% 1502
2022
Q1 		$3.65M Buy
104,400
+8,800
+9% +$257K ﹤0.01% 1652
2021
Q4 		$3.1M Buy
95,600
+2,200
+2% +$77.6K ﹤0.01% 1771
2021
Q3 		$2.75M Buy
93,400
+23,300
+33% +$654K ﹤0.01% 1842
2021
Q2 		$1.8M Buy
+70,100
New +$1M ﹤0.01% 2186

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Swiss National Bank's CERE Position: Q3 2024 in Review

Swiss National Bank sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 143,200 shares — an estimated $5.86M sold.

Swiss National Bank first reported a position in CERE in Q2 2021 and held it in 13 quarters. The position peaked at $6.05M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Swiss National Bank reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Swiss National Bank sold 143,200 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $5.86M.
  • Swiss National Bank first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 13 quarters.
  • Swiss National Bank's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $6.05M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Swiss National Bank's 13F filing for Q3 2024, filed 7 Nov 2024.